← Back to Search

Health System Vaccination Text Messages and Provider Education for Coronavirus

Q: Are any new participants currently being admitted to the clinical trial?

<p>The records on clinicaltrials.gov reveal that this medical trial is no longer taking in new patients; the last update was made on June 2nd, 2022. However, there are still 1057 other trials actively seeking out participants at present.</p>

N/A

Waitlist Available

Led By Kimberly A Fisher, M.D

Research Sponsored by University of Massachusetts, Worcester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial will test an intervention to help increase vaccination rates for vulnerable patients in Worcester, MA.

Eligible Conditions

Coronavirus
Vaccinations

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of unvaccinated patients who receive at least one dose of a COVID-19 vaccine series 12 weeks after the last text message is sent out to eligible patients

Secondary outcome measures

Proportion of unvaccinated patients who receive at least one dose of a COVID-19 vaccine series 6 months after the last text message is sent out to eligible patients.

Rate-ratio for vaccination rates between minority racial groups (Black, Latino, Asian) and the White population.

Side effects data

From 2012 Phase 3 trial • 6104 Patients • NCT01346592

27%

Injection site pain

25%

Pyrexia

14%

Decreased appetite

14%

Upper respiratory tract infection

14%

Diarrhea

10%

Injection site erythema

Nasopharyngitis

Irritability postvaccinal

Headache

Vomiting

Injection site induration

Myalgia

Hypersomnia

Injection site swelling

Fatigue

Crying

Injection site hemorrhage

Gastroenteritis

Pneumonia

Animal Bite

100%

80%

60%

40%

20%

Study treatment Arm

ATIV (6 to <72 Months)

TIV (6 to <72 Months)

Comparator TIV (6 to <72 Months)

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Multi-component patient and provider intervention to promote COVID-19 vaccinationExperimental Treatment1 Intervention

Group II: Usual careActive Control1 Intervention

Patients will receive usual care

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Health System Vaccination Text Messages and Provider Education

2022

N/A

~26120

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Massachusetts, WorcesterLead Sponsor

342 Previous Clinical Trials

950,492 Total Patients Enrolled

National Institute on Minority Health and Health Disparities (NIMHD)NIH

380 Previous Clinical Trials

1,189,536 Total Patients Enrolled

Kimberly A Fisher, M.DPrincipal InvestigatorUniversity of Massachusetts, Worcester

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any new participants currently being admitted to the clinical trial?

"The records on clinicaltrials.gov reveal that this medical trial is no longer taking in new patients; the last update was made on June 2nd, 2022. However, there are still 1057 other trials actively seeking out participants at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Intervention to Promote COVID-19 Vaccination

Kimberly Fisher 2022. "Intervention to Promote COVID-19 Vaccination". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04981392.